Finance

Beta
Senarai
Sektor ekuiti
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Buka
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
Q1 2026 earnings • in 3 days
See details
JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
USD 202.72
-0.15%
(-0.30) 1H
USD 202.72
0.00% (0.00)
Selepas waktu pejabat
Ditutup: 1 Mei, 4:00:00 PTG GMT-4  ·   USD
Semua simbol
SimbolPriceChange% Change
Generating top insights for JAZZ...
Buka
USD 204.50
High
USD 204.99
Low
USD 201.75
Mkt. cap
12.72B
Avg. vol.
896.32K
Volume
572.39K
52-wk high
USD 207.48
52-wk low
USD 97.50
EPS
-USD 5.87
Beta
0.23
Shares outstanding
62.74J
No. of employees
3K
News stories
From sources across the web
Profil
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOBruce C Cozadd
Employees2.89K
Founded2003
Headquarters-
Sector-
Websitejazzpharma.com
Next call dalam 3 hari
Sel, 5 Mei, 4:30 PTG
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (4.66 est.)USD
Revenue / Estimate
-/ (979.01J est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mac 2025
Jun 2025
Sep 2025
Dis 2025
Revenue
897.84J
1.05B
1.13B
1.20B
Cost of goods sold
74.74J
116.27J
128.88J
112.92J
Cost of revenue
74.74J
116.27J
128.88J
112.92J
Research and development expenses
180.65J
189.97J
198.20J
172.66J
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
514.01J
358.40J
379.15J
418.46J
Operating expense
849.11J
710.47J
745.72J
760.86J
Total operating expenses
923.85J
826.74J
874.60J
873.79J
Operating income
-26.01J
218.97J
251.51J
324.14J
Other non operating income
-
-
-
-
EBT including unusual items
-110.35J
-735.64J
8.99J
208.41J
EBT excluding unusual items
-80.47J
169.72J
202.99J
278.02J
Income tax expense
-17.81J
-17.17J
-242.42J
4.96J
Effective tax rate
16.14%
2.33%
-2,697.20%
2.38%
Other operating expenses
-
-
-
-
Net income
-92.54J
-718.47J
251.41J
203.45J
Net profit margin
-10.31%
-68.71%
22.33%
16.98%
Earnings per share
1.68
-8.25
8.13
6.64
Interest and investment income
-
19.10J
18.60J
20.50J
Interest expense
-53.71J
-66.46J
-67.18J
-65.91J
Net interest expenses
-53.71J
-47.36J
-48.58J
-45.41J
Depreciation and amortization charges
-
-
-
-
EBITDA
138.86J
392.98J
429.76J
503.31J
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

Tugasan saya
Anda belum membuat tugasan lagi
Tugasan anda akan dipaparkan di sini. Jadualkan tugasan dan manfaatkan Google Finance semasa anda tiada.
Templat
Ringkasan senarai amatan
Analisis prapasaran harian bagi senarai amatan anda
Pendapatan Akan Datang
Laporan pendapatan akan datang dalam minggu ini
Kemudahubahan & Jumlah yang Tidak Normal
Amaran awal kemudahubahan dan jumlah hari ini
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer